Bavarian Nordic announced an expansion of the partnership with Serum Institute of India (SII) to include a contract manufacturing agreement covering a full technology transfer of the manufacturing process for the chikungunya vaccine (CHIKV VLP) from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic Low- and Middle-Income Countries (LMICs).

This agreement builds on the existing mpox vaccine licence and manufacturing agreement with SII, and replaces the agreement previously entered with Biological E.

In addition, through this expanded collaboration, the parties will explore potential future co-development opportunities.

“We are pleased to strengthen our strategic partnership with Serum Institute of India. By leveraging the strengths of both organisations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the globe,” said Paul Chaplin, President and CEO, Bavarian Nordic.